Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease
Authors: Xi Yang, Lilit Karapetyan, John M. Kirkwood
Journal: Annals of Internal Medicine (2021)

LettersSeptember 2021Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune DiseaseXi Yang, MD, Lilit Karapetyan, MD, John M. Kirkwood, MDXi Yang, MDUniversity of Pittsburgh Medical Center, Pittsburgh, Pennsylvania, Lilit Karapetyan, MDUPMC Hillman Cancer Center, Pittsburgh, Pennsylvania, John M. Kirkwood, MDUPMC Hillman Cancer Center, Pittsburgh, PennsylvaniaAuthor, Article, and Disclosure Informationhttps://doi.org/10.7326/L21-0441 SectionsAboutFull TextPDF ToolsAdd to favoritesDownload CitationsTrack CitationsPermissions ShareFacebookTwitterLinkedInRedditEmail TO THE EDITOR: van der Kooij and colleagues' large prospective cohort study (1) shows that the objective antitumor response and incidence of high-grade immune-related adverse events with immune checkpoint inhibition are similar in patients with advanced melanoma with and without baseline autoimmune disease (AID). However, several concerns need to be addressed before drawing this conclusion.First, a considerable proportion of patients in the AID group had hypo- or hyperthyroidism (141 of 415 [34%]). As a result, the prevalence and severity of immune-related adverse events may differ if these patients are excluded. In an ongoing phase 1b trial (ClinicalTrials.gov: NCT03816345) that ...References1. van der Kooij MK, Suijkerbuijk KPM, Aarts MJB, et al.. Safety and efficacy of checkpoint inhibition in patients with melanoma and preexisting autoimmune disease. A cohort study. Ann Intern Med. 2021;174:641-8. [PMID: 33587686] doi:10.7326/M20-3419 LinkGoogle Scholar2. Johnson DB, Sullivan RJ, Ott PA, et al. Ipilimumab therapy in patients with advanced melanoma and preexisting autoimmune disorders. JAMA Oncol. 2016;2:234-40. [PMID: 26633184] doi:10.1001/jamaoncol.2015.4368 CrossrefMedlineGoogle Scholar3. Menzies AM, Johnson DB, Ramanujam S, et al. Anti-PD-1 therapy in patients with advanced melanoma and preexisting autoimmune disorders or major toxicity with ipilimumab. Ann Oncol. 2017;28:368-76. [PMID: 27687304] doi:10.1093/annonc/mdw443 CrossrefMedlineGoogle Scholar4. Danlos FX, Voisin AL, Dyevre V, et al. Safety and efficacy of anti-programmed death 1 antibodies in patients with cancer and pre-existing autoimmune or inflammatory disease. Eur J Cancer. 2018;91:21-9. [PMID: 29331748] doi:10.1016/j.ejca.2017.12.008 CrossrefMedlineGoogle Scholar Author, Article, and Disclosure InformationAffiliations: University of Pittsburgh Medical Center, Pittsburgh, PennsylvaniaUPMC Hillman Cancer Center, Pittsburgh, PennsylvaniaDisclosures: Disclosures can be viewed at www.acponline.org/authors/icmje/ConflictOfInterestForms.do?msNum=L21-0441. PreviousarticleNextarticle Advertisement FiguresReferencesRelatedDetailsSee AlsoSafety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease Monique K. van der Kooij , Karijn P.M. Suijkerbuijk , Maureen J.B. Aarts , Franchette W.P.J. van den Berkmortel , Christian U. Blank , Marye J. Boers-Sonderen , Jesper van Breeschoten , Alfonsus J.M. van den Eertwegh , Jan Willem B. de Groot , John B.A.G. Haanen , Geke A.P. Hospers , Djura Piersma , Rozemarijn S. van Rijn , Albert J. ten Tije , Astrid A.M. van der Veldt , Gerard Vreugdenhil , Michiel C.T. van Zeijl , Michel W.J.M Wouters , Olaf M. Dekkers , and Ellen Kapiteijn Safety and Efficacy of Checkpoint Inhibition in Patients With Melanoma and Preexisting Autoimmune Disease Monique K. van der Kooij , Karijn P.M. Suijkerbuijk , Olaf M. Dekkers , and Ellen Kapiteijn Metrics Cited bySafety and efficacy of immune checkpoint inhibitors in advanced cancer patients with autoimmune disease: A meta-analysisMonitoring and Management of the Patient with Immune Checkpoint Inhibitor-Induced Inflammatory Arthritis: Current Perspectives September 2021Volume 174, Issue 9Page: 1345 ePublished: 21 September 2021 Issue Published: September 2021 Copyright & PermissionsCopyright © 2021 by American College of Physicians. All Rights Reserved.PDF downloadLoading ...